Pfizer Inc. (NYSE:PFE) Position Lessened by Csenge Advisory Group
Csenge Advisory Group decreased its stake in Pfizer Inc. (NYSE:PFE) by 22.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,104 shares of the biopharmaceutical company’s stock after selling 8,213 shares during the period. Csenge Advisory Group’s holdings in Pfizer were worth $1,065,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Kinloch Capital LLC bought a new stake in Pfizer during the 4th quarter valued at $25,000. Alpha DNA Investment Management LLC bought a new stake in Pfizer during the 4th quarter valued at $26,000. Penbrook Management LLC bought a new stake in Pfizer during the 4th quarter valued at $27,000. Orion Capital Management LLC bought a new stake in Pfizer during the 4th quarter valued at $29,000. Finally, Merrion Investment Management Co LLC bought a new stake in Pfizer during the 4th quarter valued at $30,000. 67.36% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently issued reports on PFE. DZ Bank reiterated a “buy” rating and set a $41.00 price target on shares of Pfizer in a research report on Wednesday, February 3rd. TheStreet cut Pfizer from a “b” rating to a “c+” rating in a research report on Friday, March 5th. Mizuho lowered their price target on Pfizer from $44.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, February 3rd. SVB Leerink lowered their price target on Pfizer from $40.00 to $39.00 and set a “market perform” rating on the stock in a research report on Thursday, April 1st. Finally, Berenberg Bank restated a “neutral” rating and issued a $38.00 target price on shares of Pfizer in a report on Tuesday, March 23rd. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus target price of $38.47.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. Pfizer’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.55 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 4th. Investors of record on Friday, May 7th will be given a dividend of $0.39 per share. The ex-dividend date is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a yield of 3.92%. Pfizer’s payout ratio is 52.88%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Read More: Why are trading ranges significant?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.